chronic hepatitis C patients with or without compensated cirrhosis
Conditions
Interventions
None listed
Sponsors
Hokkaido University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Subjects Subjects will be chronic hepatitis C patients with or without compensated cirrhosis who visit or are admitted to the study sites participating in this study between the day of permission to conduct the study and June 2025. Inclusion Criteria 1. The subject is aged 20 years or older at the time of informed consent. 2. Patients with chronic hepatitis C with or without compensated cirrhosis treated with the combination of sofosbuvir and velpatasivir for 12 weeks in routine clinical practice 3. A person who has received sufficient explanation before participation in this research and obtained voluntary consent of the subject himself/herself with sufficient understanding
Exclusion criteria
Exclusion criteria: Exclusion Criteria 1.Patients who are judged by the research lead to be inappropriate for participation in this review 2.Other persons who are judged by the principal investigator to be inappropriate as research subjects *Patients who discontinue treatment due to adverse drug reactions, etc. will not be excluded from the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HCV-RNA conversion rate at 12 weeks after the end of treatment, occurrence of adverse reactions | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Assessment of the number of visits during treatment, therapeutic effects, and safety 2) Emergence of drug resistance mutations in non-responders 3) Improvement in liver fibrosis and Child-pugh score 4) AFP improvement effect 5) Glucose-Lipid-Related Factors and Therapeutic Effects 6) Effect of virus elimination on renal disorder Adverse events | — |
Countries
Japan
Contacts
Public ContactGOKI suda
Hokkaido University Hospital Department of Gastroenterology and Hepatology
Outcome results
None listed